Cutting-Edge Technology and Mitochondrial Diseases - Where is the Limit?
By Dusko Ilic,
BioNews
| 07. 27. 2015
Untitled Document
In their latest study, published in the Nature, Shoukrat Mitalipov and collaborators, including Juan Carlos Izpisua Belmonte, reported on two potential 'gene correction' strategies that can help patients with mitochondrial diseases (1, BioNews 811). Both approaches are built on the idea of mitochondria segregation phenomenon, reported for the first time by a group from the Mayo clinic in Rochester, Minnesota(2).
Basically, in proliferating cells the mitochondria segregate spontaneously and, if we start with a heteroplasmic cell containing a mix of healthy, wild-type and mutation-carrying mitochondria, after multiple cell divisions daughter cells will segregate into three major groups. The first will contain predominantly healthy, wild-type mitochondria with a few-to-nil mitochondria that carry the mutation, while the second is quite opposite – a vast majority of mitochondria will be carrying the deleterious mutation and almost none will be healthy. The third group will be heteroplasmic, containing various degrees of mixed normal and mutation-carrying mitochondria.
Read more...
Related Articles
By Courtney Withers and Daryna Zadvirna, ABC News | 12.03.2025
Same-sex couples, single people, transgender and intersex West Australians will be able to access assisted reproductive technology (ART) and surrogacy, almost a decade after reforms were first promised.
The landmark legislation, which removes the requirement for people to demonstrate medical...
By Rachel Hall, The Guardian | 11.20.2025
Couples are needlessly going through IVF because male infertility is under-researched, with the NHS too often failing to diagnose treatable causes, leading experts have said.
Poor understanding among GPs and a lack of specialists and NHS testing means male infertility...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...